Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Apex1 safeguards genomic stability to ensure a cytopathic T cell fate in autoimmune disease models
Xiang Xiao, … , Zhiqiang Zhang, Xian C. Li
Xiang Xiao, … , Zhiqiang Zhang, Xian C. Li
Published December 31, 2024
Citation Information: J Clin Invest. 2025;135(4):e183671. https://doi.org/10.1172/JCI183671.
View: Text | PDF
Research Article Autoimmunity Immunology

Apex1 safeguards genomic stability to ensure a cytopathic T cell fate in autoimmune disease models

  • Text
  • PDF
Abstract

T cells have a remarkable capacity to clonally expand, a process that is intricately linked to their effector activities. As vigorously proliferating T cell also incur substantial DNA lesions, how the dividing T cells safeguard their genomic integrity to allow the generation of T effector cells remains largely unknown. Here we report the identification of the apurinic/apyrimidinic endonuclease-1 (Apex1) as an indispensable molecule for the induction of cytopathic T effectors in mouse models. We demonstrate that conditional deletion of Apex1 in T cells resulted in a remarkable accumulation of baseless DNA sites in the genome of proliferating T cells, which further led to genomic instability and apoptotic cell death. Consequently, Apex1-deleted T cells failed to acquire any effector features after activation and failed to mediate autoimmune diseases and allergic tissue damages. Detailed mutational analyses pinpointed the importance of its endonuclease domain in the generation of T effector cells. We provide further evidence that inhibiting the base repair activities of Apex1 with chemical inhibitors similarly abrogated the induction of autoimmune diseases. Collectively, our study suggests that Apex1 serves as a gatekeeper for the generation of cytopathic T cells and that therapeutically targeting Apex1 may have important clinical implications in the treatment of autoimmune diseases.

Authors

Xiang Xiao, Yong Du, Si Sun, Xiaojun Su, Junji Xing, Guangchuan Wang, Steven M. Elzein, Dawei Zou, Laurie J. Minze, Zhuyun Mao, Rafik M. Ghobrial, Ashton A. Connor, Wenhao Chen, Zhiqiang Zhang, Xian C. Li

×

Figure 5

Inhibition of Apex1 base repair activities, but not redox functions, prevents the induction of EAE.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of Apex1 base repair activities, but not redox functions, pre...
(A) A diagram showing the workflow for EAE induction and treatment protocols. WT B6 mice were immunized with MOG/complete Freund’s adjuvant on days 0 and 1 and subsequently treated i.p. with vehicle control (n = 5), Apex1 inhibitor APX3330 (100 mg/kg, twice daily) (n = 5), starting on day 0 for 28 days, or methoxamine hydrochloride (MH, 75 mg/kg, every other day) starting on day 1 for 14 days (n = 7) or delayed MH treatment starting on day 7 for 11 days (n = 7). (B) Incidence and clinical scores of EAE in treated mice. (C) Representative tissue pathology of spinal cord sections on day 22 (n = 3 mice per group). Arrowheads indicate inflammatory cell infiltrates. Scale bars: 100 μm. (D and E) Representative flow cytometry plots (D) and bar graphs (E) showing effector phenotypes and inflammatory cytokine expression by CD4+ T cells obtained from CNS of treated mice 22 days after EAE induction (n = 3 mice per group). Data are presented as mean ± SD. The P values are from 2-way ANOVA with Dunnett’s post hoc test (B) and 1-way ANOVA with Šidák’s post hoc test (E).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts